Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
The Role of CD248 in the Salmonella-induced Intestinal Fibrosis Model
EF 2011-12
Résumé
A common complication of chronic infections and inflammation of the intestines, including Crohn's Disease and Ulcerative Colitis, is scarring or so-called fibrosis. Fibrosis may cause chronic pain and/or severe constipation requiring surgery. Despite advances in our understanding of inflammatory bowel diseases, there are no therapies which entirely halt their progression and the development of the terrible complications associated with fibrosis. Further research is therefore urgently needed.
In the past decade, a novel protein that holds much promise as a therapeutic target against inflammation and fibrosis has been identified. This protein, known as CD248 or endosialin, is not present in healthy adult tissues but is abundant during inflammation. Dr. Edward Conway's laboratory recently demonstrated that reducing the amount of CD248 in mice will reduce the severity of arthritis, another inflammatory disease. We predict that by altering the amount of CD248 in the gut, we might reduce the amount of fibrosis that occurs in inflammatory or infectious bowel disease. This would justify further investigations to develop drugs to reduce the amount of CD248 in the bowel in those diseases. Our preliminary studies do indeed suggest that CD248 contributes to the fibrosis, as CD248 is increased during intestinal fibrosis. We still must, however, determine if and how it does contribute. Our goal, therefore, is to examine the role of CD248 in intestinal fibrosis using mice models. We hope to provide evidence that interfering with the function or amount of CD248 will reduce inflammation and intestinal fibrosis. This new knowledge may then eventually be useful in the development of treatment options against intestinal fibrosis in humans.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
255318
Name
Wat Jovian
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
The Role of CD248 in the Salmonella-induced Intestinal Fibrosis Model
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cell Signalling; Fibrosis; Gastrointestinal Diseases; Immunology; Infection; Inflammation; Murine Models; Pathogenesis
Abstract
A common complication of chronic infections and inflammation of the intestines, including Crohn's Disease and Ulcerative Colitis, is scarring or so-called fibrosis. Fibrosis may cause chronic pain and/or severe constipation requiring surgery. Despite advances in our understanding of inflammatory bowel diseases, there are no therapies which entirely halt their progression and the development of the terrible complications associated with fibrosis. Further research is therefore urgently needed.
In the past decade, a novel protein that holds much promise as a therapeutic target against inflammation and fibrosis has been identified. This protein, known as CD248 or endosialin, is not present in healthy adult tissues but is abundant during inflammation. Dr. Edward Conway's laboratory recently demonstrated that reducing the amount of CD248 in mice will reduce the severity of arthritis, another inflammatory disease. We predict that by altering the amount of CD248 in the gut, we might reduce the amount of fibrosis that occurs in inflammatory or infectious bowel disease. This would justify further investigations to develop drugs to reduce the amount of CD248 in the bowel in those diseases. Our preliminary studies do indeed suggest that CD248 contributes to the fibrosis, as CD248 is increased during intestinal fibrosis. We still must, however, determine if and how it does contribute. Our goal, therefore, is to examine the role of CD248 in intestinal fibrosis using mice models. We hope to provide evidence that interfering with the function or amount of CD248 will reduce inflammation and intestinal fibrosis. This new knowledge may then eventually be useful in the development of treatment options against intestinal fibrosis in humans.
Competitiondate
201202
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wat, Jovian
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~